Log in  First Connection?

Blood CancerArchives

Plasma proteome profiles of standard-risk and high-risk childhood acute lymphoblastic leukemia
Blood Cancer
 1 min.

 Published on 02/06/2026 |  Original article (Full-text)  | Najia Tabassum et al. | Expert Review of Proteomics 2026; aop:10.1080/14789450.2026.2676596

This exploratory study aimed to characterize plasma proteome profiles across different risk groups and investigate underlying molecular mechanisms using bioinformatics approaches. This is a case-control study. Plasma samples from 15 children per group- standard-risk B-ALL (B-ALL SR), high-risk B-ALL...

Real-world venetoclax dosing patterns and treatment persistence in patients with acute myeloid leukemia: a community pharmacy database study in Japan
Blood Cancer
 1 min.

 Published on 26/05/2026 |  Original article (Full-text)  | Yuki Goshima a b et al. | Leukemia & Lymphoma 2026; aop:10.1080/10428194.2026.2665793

Venetoclax (VEN)-based regimens are widely used for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, but VEN dosing patterns and their relation to treatment persistence are not well described. We conducted a retrospective longitudinal study using de-identified...

Long non-coding RNAs and survival outcomes in chronic lymphocytic leukemia
Blood Cancer
 1 min.

 Published on 19/05/2026 |  Original article (Full-text)  | Teodora Karan-Djurasevic et al. | Pharmacogenomics 2026; 27(3-4): 159-177

Chronic lymphocytic leukemia (CLL) is a highly heterogeneous hematological malignancy characterized by pronounced differences in clinical course and genetic . While research has historically focused on alterations in protein-coding genes, it is increasingly evident that the non-coding transcriptome plays...

Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia
Blood Cancer
 1 min.

 Published on 12/05/2026 |  Original article (Full-text)  | Fang Cheng et al. | Haematologica. Volume 111(4).

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder typically managed with BCR::ABL1 tyrosine kinase inhibitors (TKI). However, it can progress from chronic phase (CML-CP) to blast phase (CML-BP), during which BCR::ABL1 kinase domain (KD) genetic variants (e.g., T315I, Y253H) and aberrant...

Asparaginase activity levels and toxicity in children and adolescents with acute lymphoblastic leukemia
Blood Cancer
 1 min.

 Published on 05/05/2026 |  Original article (Full-text)  | Marie-Claude Pelland-Marcotte a et al. | Leukemia & Lymphoma 2026; aop:10.1080/10428194.2026.2656726

Asparaginase (ASP) is a critical treatment component of acute lymphoblastic leukemia (ALL), yet associated with potentially severe complications. We assessed whether serum asparaginase activity (SAA) is associated with development of venous thrombosis, acute pancreatitis, bleeding and/or hypersensitivity...